Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Nula-cel in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease

NCT04819841 is registered in ClinicalTrials.gov with Kamau Therapeutics as lead sponsor.

NCT NCT04819841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04819841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Nula-cel in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease
Lead sponsor
Kamau Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 15, 2021
Completion date
December 31, 2028
Enrollment
15 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease